TransMedics Secures Full FDA Approval for Landmark Heart Transplant Trial
Event summary
- TransMedics received full FDA IDE approval for its Next-Generation OCS ENHANCE Heart trial on February 9, 2026.
- The trial is the largest heart preservation for transplant study ever, with over 650 patients across two parts.
- Part B aims to demonstrate the superiority of OCS Heart perfusion over static cold storage for DBD hearts.
- This follows full FDA approval for the DENOVO Lung IDE trial in January 2026 and conditional approval for the ENHANCE Heart trial in August 2025.
The big picture
TransMedics' full FDA approval for the ENHANCE Heart trial positions it to potentially disrupt the organ transplant market by proving the superiority of its perfusion technology over traditional cold storage methods. The trial's scale and design could set a new standard for heart preservation, addressing critical unmet needs in transplant therapy. Success in these trials would significantly expand TransMedics' market opportunities in heart and lung transplantation.
What we're watching
- Trial Execution
- How TransMedics will manage the largest heart preservation trial and maintain enrollment momentum.
- Regulatory Milestones
- Whether the outcomes of ENHANCE and DENOVO trials will accelerate FDA approvals for broader clinical indications.
- Market Adoption
- The pace at which transplant centers adopt OCS technology following positive trial results.
Related topics